III-A type CRISPR-Cas system inhibitor AcrIIIA2 and application thereof
A III-A, 1.III-A technology, applied in the field of RNA editing, can solve problems such as unknown consequences
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0022] Identification and cloning of AcrIIIA1 and AcrIIIA2
[0023] (1) Biological information screening and analysis of candidate AcrIIIAs genes
[0024] According to the presence of RNA sequences that can be targeted and recognized by type III-A CRISPR-Cas in the bacterial transcriptome, it is suggested that the bacteria's own genome may contain inhibitors that prevent the RNA editing activity of type III-A CRISPR-Cas systems. According to this principle, in the Staphylococcus argenteus 3688STDY6125118 bacterial gene sequence (https: / / www.ncbi.nlm.nih.gov / , accession number: NZ_FQLY01000002.1) containing the III-A type CRISPR-Cas system, through Self-Targeting Space Search Platform (SSTS) analysis to obtain sequence sites that can be targeted and recognized by Type III-A CRISPR-Cas ( figure 1 Middle A), implying that there may be an inhibitor of RNA-cleaving activity of type III-A CRISPR-Cas in S. argenteus 3688STDY6125118. Because the Acr gene usually clusters with the Ac...
Embodiment 2
[0037] AcrIIIA1 and AcrIIIA2 inhibit RNA-cleaving activity of type III-A CRISPR-Cas in bacteria
[0038] To verify whether AcrIIIA1 and AcrIIIA2 inhibit the activity of type III-A CRISPR-Cas in bacteria. First, the pCRISPR MS2 recombinant plasmid was constructed to obtain the crRNA expression vector used to recognize the rep RNA of MS2 RNA phage. The pre-crRNA sequence is synthesized by GeneUniversal, such as figure 2 As shown in A, the pre-crRNA was linked to the pBluescript II sk(+)1 vector by T4 DNA ligase to obtain the recombinant plasmid pCRISPR MS2. Secondly, pET28a-AcrIIIA1, pET28a-AcrIIIA2 or pET28a, T7-pCas / Csm plasmid and pCRISPR MS2 plasmid were transformed into competent cells to obtain E. coli c-3000 / T7-pCas / Csm / pCRISPR MS2 / pET28a, E. The coli c-3000 / T7-pCas / Csm / pCRISPR MS2 / pET28a-AcrIIIA1 and E.coli c-3000 / T7-pCas / Csm / pCRISPR MS2 / pET28a-AcrIIIA2 strains were used for the plaque formation experiment of MS2 RNA phage invasion ( figure 2 Middle A). The obtain...
Embodiment 3
[0041] AcrIIIA1 and AcrIIIA2 inhibit the editing activity of type III-A CRISPR-Cas RNA in mammalian cells
[0042] In order to verify whether AcrIIIA1 and AcrIIIA2 inhibit type III-A CRISPR-CasRNA editing activity in HEK293T cells, the effect of AcrIIIA1 and AcrIIIA2 on type III-A CRISPR-Cas cutting influenza virus (Influenza A virus, IAV) was detected in HEK293T cells . Using Lipofectamine TM CRISPRMAX TM Transfection Reagent (Thermo Fisher Scientific) transfected HEK293T cells with type III-A CRISPR-Cas complex targeting IAV and AcrIIIA1 or AcrIIIA2 protein, then infected IAV virus (MOI=0.01 and 0.5, multiplicity of infection), and detected IAV virus RNA and virus titers ( image 3 Middle A). The process is as follows:
[0043] 1) Ni column affinity chromatography purification of AcrIIIA1, AcrIIIA2 and III-A type CRISPR-Cas proteins:
[0044] The constructed pET28a-His-AcrIIIA1, pET28a-His-AcrIIIA1, and T7-pCas / Csm / His-Csm2 plasmids were transformed into E.coli BL21 c...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


